Agenus shared on LinkedIn:
“As Agenus Chief Development Officer, Dr. Richard Goldberg explains, our goal is to expand the CRC patient population that can benefit from immunotherapy-based cancer treatments.
Learn more about immunotherapy on our website.”
Read more about Colorectal Cancer.